Department of Hematology, Osaka International Cancer Institute, Osaka, Japan.
Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
Ann Hematol. 2021 Jan;100(1):157-165. doi: 10.1007/s00277-020-04308-8. Epub 2020 Oct 21.
Peripheral T cell lymphomas (PTCL) are a heterogeneous group of non-Hodgkin lymphomas with poor outcomes. Adult T cell leukemia-lymphoma (ATL) and PTCL-not otherwise specified (PTCL-NOS)-are 2 common mature T cell lymphomas in Japan. Since it is unclear whether novel agents and treatment strategies incorporating hematopoietic cell transplantation have contributed to improved clinical outcomes in the real world, we performed a retrospective analysis using data from the population-based Osaka Cancer Registry. From 1977 to 2014, 1274 and 1143 patients were diagnosed with ATL or PTCL-NOS, respectively. Recently, the incidence of both diseases has gradually increased, and the age at diagnosis has risen. The 3-year overall survival (OS) rates in ATL patients were 12.0% in era 1 (1977-1999), 12.4% in era 2 (2000-2008), and 17.5% in era 3 (2009-2014) (P < 0.001). The 3-year OS rates in PTCL-NOS patients were 27.6% in era 1, 36.2% in era 2, and 35.0% in era 3 (P = 0.049). In conclusion, the incidences of ATL and PTCL-NOS have been increasing, particularly in elderly individuals. Clinical outcomes have improved in recent decades but are still unsatisfactory in both diseases. Thus, effective new treatment strategies incorporating novel agents are needed to further improve clinical outcomes in patients with ATL and PTCL-NOS.
外周 T 细胞淋巴瘤 (PTCL) 是一组异质性非霍奇金淋巴瘤,预后较差。成人 T 细胞白血病/淋巴瘤 (ATL) 和未特指的 PTCL-NOS (PTCL-NOS) 是日本 2 种常见的成熟 T 细胞淋巴瘤。由于尚不清楚新型药物和包含造血细胞移植的治疗策略是否有助于改善真实世界中的临床结局,我们使用基于人群的大阪癌症登记处的数据进行了回顾性分析。1977 年至 2014 年,分别诊断出 1274 例和 1143 例 ATL 或 PTCL-NOS 患者。最近,这两种疾病的发病率逐渐增加,诊断时的年龄也在上升。ATL 患者的 3 年总生存 (OS) 率在 1 时代 (1977-1999 年) 为 12.0%,2 时代 (2000-2008 年) 为 12.4%,3 时代 (2009-2014 年) 为 17.5%(P < 0.001)。PTCL-NOS 患者的 3 年 OS 率在 1 时代为 27.6%,2 时代为 36.2%,3 时代为 35.0%(P = 0.049)。总之,ATL 和 PTCL-NOS 的发病率一直在增加,尤其是在老年人中。近几十年来,临床结局有所改善,但在这两种疾病中仍然不尽如人意。因此,需要包含新型药物的有效新治疗策略来进一步改善 ATL 和 PTCL-NOS 患者的临床结局。